This Isn't Experimental: Breast Cancer Just Got 3 NEW DRUGS | Cancer Drug Designer

The drug oncologists have used for 25 years just got outperformed. Three times. Here's what's next. #BreastCancer #SERD #ElevatingCancerTreatment. Longer version deep dive here:    • This Isn't Experimental: The Breast Cancer...   👉 Get your free guide, '10 Things to Elevate Your Chemo Journey,' here: https://elevatingcancertreatment.com/... 👉 Want personalized attention to help you along your individual cancer journey? Explore 1:1 sessions with Dr. Chaplin: https://elevatingcancertreatment.com/... 👉 Want to find out more about Dr. Chaplin's journey of bringing a cancer drug to market? Explore his innovations: https://elevatingcancertreatment.com/... -------------------------------------------- V I D E O S T O W A T C H N E X T : 👉 This Isn't Experimental: The Breast Cancer Update You Missed | Cancer Drug Designer    • This Isn't Experimental: The Breast Cancer...   👉 Your Oncologist Might Be Missing the Most Important Part of Your Cancer Report    • Your Oncologist Might Be Missing the Most ...   👉 Real Cancer Cases: What a Drug Designer Catches That Oncologists Miss | Cancer Drug Designer    • Real Cancer Cases: What a Drug Designer Ca...   -------------------------------------------- Inquiries: [email protected] -------------------------------------------- Citations: Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer. https://pubmed.ncbi.nlm.nih.gov/27269... ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer. https://pubmed.ncbi.nlm.nih.gov/32546... ESR1 mutations — a mechanism for acquired endocrine resistance in breast cancer. https://pubmed.ncbi.nlm.nih.gov/26122... FES-PET imaging of estrogen receptor occupancy. https://pubmed.ncbi.nlm.nih.gov/20855... Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer (VERITAC-2). https://pubmed.ncbi.nlm.nih.gov/40454... Camizestrant + CDK4/6 inhibitor for treatment of emergent ESR1 mutations during first-line endocrine-based therapy (SERENA-6). https://pubmed.ncbi.nlm.nih.gov/39481... Phase III evERA data: giredestrant-everolimus significantly improved PFS in ER-positive advanced breast cancer. https://www.roche.com/media/releases/... Giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer (lidERA). https://www.gene.com/media/press-rele... -------------------------------------------- #chemotherapy #chemo #breastcancer #breastcancertreatment #breastcancerpatient #metastaticbreastcancer #hormonereceptorpositive #estrogenreceptorpositive #ESR1 #ESR1mutation #liquidbiopsy #circulatingtumorDNA #ctDNA #aromataiseinhibitor #tamoxifen #fulvestrant #vepdegestrant #camizestrant #giredestrant #protac #SERD #selectiveestrogeneReceptordegrader #CDK46inhibitor #ibrance #targetedtherapy #breastcancernews #newcancertreatment #cancertreatment #cancer #chemotherapy #oncology #biomarkers #genomics #cancerdoctor #cancerpatient #cancerremission #cancerrecurrence #cancersurvivor #clinicaltrials #scienceexplained #elevatingcancertreatment #precisionmedicine #cancerimmunotherapy -------------------------------------------- Disclaimer: The information provided in this video is for educational and informational purposes only, and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have heard or read in this video or on this channel. Reliance on any information provided by Dr. Jay Chaplin or Elevating Cancer Treatment is solely at your own risk. Dr. Jay Chaplin is a scientist and drug developer, not a medical doctor providing patient care. The content presented here reflects general scientific understanding and research, and may not be applicable to your individual health circumstances. Individual medical conditions and treatments vary, and no two situations are exactly alike. Always consult with your personal healthcare provider before making any decisions about your health or treatment plan.